

Risperidone Treatment in 12 Children With Developmental Disorders and Attention-Deficit/Hyperactivity Disorder

Valsamma Eapen, M.R.C.Psych., and A. K. Gururaj, F.R.C.P.I.

Background: Risperidone is a novel antipsychotic drug that has been tried in the treatment of several child psychiatric disorders. In an open clinical study, we evaluated the safety and efficacy of risperidone in children with developmental disorder and behavioral problems including attention-deficit/hyperactivity disorder (ADHD).

Method: Twelve patients aged 4 to 14 years who had a DSM-IV–diagnosed developmental disorder and ADHD in addition to other behavioral problems, in particular aggression, were treated with risperidone for a period of up to 2 years with daily doses ranging from 1 to 3 mg. Data were gathered from December 2002 to December 2004.

Results: A positive clinical response was noted in 9 of the 12 patients within 3 months of study recruitment according to the Clinical Global Impressions-Improvement scale. Risperidone was well tolerated by all 12 patients. The most commonly reported side effect was sedation, which necessitated dosage reduction in 2 patients, but not discontinuation.

Conclusions: Our findings suggest that risperidone may be an effective and safe treatment for children and adolescents with developmental disorder and disruptive behaviors.

(*Prim Care Companion J Clin Psychiatry* 2005;7:221–224)

Received Feb. 12, 2005; accepted June 22, 2005. From the Department of Psychiatry (Dr. Eapen) and the Department of Pediatrics (Dr. Gururaj), Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.

Drs. Eapen and Gururaj report no financial relationship or affiliation relevant to the subject of this article.

Corresponding author and reprints: Valsamma Eapen, M.R.C.Psych., Faculty of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, United Arab Emirates (e-mail: veapen@uaeu.ac.ae).

Behavioral problems often coexist with developmental and learning disorders, and in these instances, irritability, aggression, hyperactivity, insomnia, and self-injurious behaviors are the main features. Reports have been published indicating that risperidone is effective in treating behavioral problems in patients with mental retardation^{1,2} and developmental disabilities^{3,4} and

in children with autism and other pervasive developmental disorders.^{5–8} A large double-blind, placebo-controlled study⁶ of risperidone for the treatment of autism and serious behavioral disorders published recently showed the efficacy of the drug in the treatment of tantrums, aggression, and self-injurious behavior in children with these disorders. A few other reports have suggested its usefulness in children with a wide range of behavioral problems, including aggression and self-injurious behaviors,¹ aberrant behaviors,⁹ pathologic aggression,¹⁰ explosive aggressive autism,¹¹ and comorbid attention-deficit/hyperactivity disorder (ADHD) and conduct disorder,¹² as well as aggressive behavior in the context of mood disorders.¹³ This article reports on the open clinical experience of treating with risperidone 12 children who had a developmental disorder and comorbid ADHD.

PATIENTS AND METHODS

In this series of 12 patients, the subjects' ages ranged from 4 to 14 years (mean = 7.5 years, SD = 3.513); all patients were male with the exception of 1. All of the patients referred to the child psychiatry and neurodevelopmental clinics from the primary health and school health clinics for the Al Ain Medical District of United Arab Emirates over a period of 1 year were included in the study. Informed consent was obtained from the patients' guardians, and Declaration of Helsinki guidelines were followed. Assessments were made at the University Teaching Hospital clinics. Data were gathered from December 2002 to December 2004.

All of the children were evaluated by a child psychiatrist, and diagnoses were made according to the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (DSM-IV).¹⁴ A checklist based on the DSM-IV criteria was used, and corroborative information was obtained using the Arabic version of the Conners' Parent Rating Scale or Conners' Teacher Rating Scale¹⁵ during the initial evaluation. ADHD was present in all of the patients (8 had the "combined" subtype and 4 had the "hyperactive" subtype of ADHD) in addition to other disruptive behaviors (Table 1). The children reported here were clinically heterogeneous, with different DSM-IV diagnoses (see Table 1), but they all had a developmental

Table 1. Characteristics of Children With Developmental Disorders and Disruptive Behaviors Treated With Risperidone

Patient	Age (y)	Sex	Initial Complaints	Diagnosis	Other Drugs Used Previously	Risperidone Treatment			Side Effects
						Dose	Duration (mo)	Outcome (CGI-I score)	
1	4	M	Poor sleep, hyperactivity, impaired social behavior, speech regression, poor appetite, repetitive behavior	ADHD, childhood disintegrative disorder	Carbamazepine	0.5–1 mg/d	23	Improved (+2) repetitive behaviors, ADHD symptoms, sleep, and appetite	None
2	4.5	M	Hyperactivity, aggression, short attention span, disruptive behavior, impulsivity, speech delay	ADHD, mixed receptive-expressive language disorder	Methylphenidate	0.5–1 mg/d	2	Hyperactivity worse (-1); drug discontinued	Worsening of hyperactivity
3	13	F	Global developmental delay, hyperactivity, impulsivity, inattention, violent behavior	ADHD, moderate MR	None	0.5–1 mg/d	22	Improved (+1) ADHD symptoms	None
4	4	M	Developmental delay, speech delay, poor social attachment, hyperactivity, stereotypic behaviors, mannerisms, attachment to inanimate objects, poor eye contact	Infantile autism, ADHD, cerebellar vermis hypoplasia, right temporal arachnoid cyst	Methylphenidate, fluoxetine, clonidine	0.5–1 mg/d	1	Drug discontinued because of worsening of behaviors (-2)	Worsening of behaviors
5	14	M	Impulsivity, hyperactivity, inattention, poor sleep, developmental delay	ADHD, mild MR	Chlorpromazine, thioridazine	0.5–3 mg/d	18	Improved (+2)	Sedation; dose reduced to 2 mg
6	10	M	Hyperactivity, impulsivity, inattention, aggression, developmental delay	ADHD, mild MR	Methylphenidate, clonidine, haloperidol, clonazepam	0.5–2 mg/d	16	Improved (+1)	None
7	10	M	Developmental delay, short attention span, hyperactivity, impulsivity, aggression, poor sleep, self-injurious behavior	ADHD, cerebral palsy, mild MR	Carbamazepine, haloperidol, thioridazine, fluoxetine	0.5–1 mg/d	16	Improved (+3) self-injurious behavior, hyperactivity, inattention	Tiredness
8	5	M	Hyperactivity, irritability, impulsivity, poor sleep, inattention, delayed speech	ADHD, moderate MR	None	0.5–1 mg/d	15	Improved (+2) ADHD symptoms, sleep	None
9	8	M	Learning problems, aggression, disruptive behavior, hyperactivity, impulsivity, motor tics, poor frustration tolerance	ADHD, mild MR, chronic tic disorder	Haloperidol	0.5–2 mg/d	3	No improvement (0); drug discontinued	None
10	6	M	Hyperactivity, disruptive behavior, loss of cognitive abilities and speech, regression in social abilities, language comprehension, and communication	Childhood disintegrative disorder, ADHD (excluded Landau-Kleffner syndrome, ESES, etc)	Haloperidol	0.5–3 mg/d	11	Improved (+3) behavior, speech and social skills	None
11	5	M	EEG: nonspecific changes Impulsivity, excitability, hyperactivity, aggression, inattention, deficits in speech and social development	ADHD, PDD-NOS	Methylphenidate	0.5–3 mg/d	8	Improved (+2) ADHD symptoms	Sedation; dose reduced to 2 mg
12	6	M	Delayed speech, stuttering, poor attention, distractibility, hyperactivity	ADHD, mixed receptive-expressive language disorder, stuttering	Clonidine	0.5–2 mg/d	7	Improved (+2) ADHD symptoms and stuttering	Weight gain

Abbreviations: ADHD = attention-deficit/hyperactivity disorder, CGI-I = Clinical Global Impressions-Improvement scale, EEG = electroencephalogram, ESES = electrical status epilepticus during sleep, F = female, M = male, MR = mental retardation, MRI = magnetic resonance imaging, PDD-NOS = pervasive developmental disorder not otherwise specified.

disorder (6 had mental retardation, 4 had pervasive developmental disorder, and 2 had communication disorder).

Risperidone treatment was started in doses of 0.5 mg once daily and increased gradually (in increments of 0.5 mg per month) to a maximum of 3 mg per day. Clinical efficacy was assessed on a monthly basis using the Clinical Global Impressions-Improvement scale (CGI-I),¹⁶ and parents were prompted to report commonly observed side effects such as sedation, weight or appetite changes, tiredness, and extrapyramidal side effects.

RESULTS

Clinical improvement was noted in 9 patients within 3 months of recruitment into the study (Table 1): scores on the CGI-I indicated mild improvement (score of +1) in 2 patients (cases 3, 6), moderate improvement (score of +2) in 5 (cases 1, 5, 8, 11, 12), significant improvement (score of +3) in 2 (cases 7, 10), and no change (score of 0) in 1 (case 9). Symptoms were reported to be worse (score of -1) in 1 patient (case 2) and much worse (score of -2) in another (case 4). Mean CGI-I score was 1.25 (SD = 1.545). Risperidone was effective in improving ADHD, aggression, and self-injurious behaviors. Sedation was reported in 2 patients, necessitating reduction in dosage but not discontinuation. The other side effects reported included tiredness and weight gain. No patients experienced extrapyramidal symptoms. Those who showed a positive clinical response were followed up for periods ranging from 12 to 23 months.

DISCUSSION

Although psychostimulants remain the mainstay of pharmacologic treatment for ADHD, they may not be tolerated by some children, may be ineffective in some, and in yet others may exacerbate a comorbid medical condition such as seizures or tics. Furthermore, most of the conventional antipsychotics used in these situations do not combat persistent irritability, extreme aggression, and other maladaptive behaviors, which often coexist in children with developmental disorders. In our cohort, risperidone was also used for different reasons including concern about the epileptogenic potential of certain drugs in the context of nonspecific electroencephalographic changes, precipitation of tics with methylphenidate, and undesirable side effects or poor response to alternative pharmacologic interventions.

Risperidone has been noted to be useful for insomnia in pervasive developmental disorder¹⁷ and for behavioral problems in developmentally disabled children¹⁸ and in adults with profound retardation and autism.¹⁹ Our findings that risperidone was effective in improving ADHD, aggression, and self-injurious behaviors suggest that risperidone has promise for the treatment of children with

developmental disorders and disruptive behaviors. Furthermore, there was improvement in coexisting sleep and appetite problems. The drug was well tolerated by the children in the dosages used (1–3 mg). The most common side effect reported was sedation in 2 patients, followed by tiredness and weight gain in 1 patient each. Earlier studies have reported weight gain,²⁰ chorea and dyskinesia,²¹ reversible withdrawal dyskinesia,²² and facial dystonia and amenorrhea²³ with the use of risperidone. However, in a study by Simon and colleagues,²⁴ traditional antipsychotics were substituted with risperidone in 10 individuals with mental retardation, and all participants evidenced improvement or resolution in side effects attributed to previous antipsychotic medication, with no worsening in behavioral or psychiatric status. Furthermore, Zuddas et al.²³ and Croonenberghs et al.²⁵ observed in their 1-year follow-up studies that risperidone is relatively safe for long-term treatment of behavioral problems.

In this study, risperidone was used for periods of up to 2 years with no undesirable effects. Because it is the usual clinical practice that children who show short-term benefit from a drug will be maintained on treatment with the medication indefinitely, it is important to evaluate the longer-term effectiveness and safety of risperidone in this population.

Drug names: carbamazepine (Carbatrol, Equetro, and others), chlorpromazine (Thorazine, Sonazine, and others), clonazepam (Klonopin and others), clonidine (Catapres, Duraclon, and others), fluoxetine (Prozac and others), haloperidol (Haldol and others), methylphenidate (Ritalin, Metadate, and others), risperidone (Risperdal).

REFERENCES

1. Cohen SA, Ihrig K, Lott RS, et al. Risperidone for aggression and self-injurious behavior in adults with mental retardation. *J Autism Dev Disord* 1998;28:229–233
2. Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. *Psychopharmacol Bull* 1996;32:721–729
3. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. *J Clin Psychiatry* 2001;62:239–248
4. Hardan A, Johnson K, Johnson C, et al. Risperidone treatment of children and adolescents with developmental disorders. *J Am Acad Child Adolesc Psychiatry* 1996;35:1551–1556
5. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of behavioral symptoms in children with autistic and other pervasive developmental disorders. *Pediatrics* 2004;114:634–641
6. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. *N Engl J Med* 2002;347:314–321
7. McDougle CJ, Holmes JP, Carlson DC, et al. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. *Arch Gen Psychiatry* 1998;55:633–641
8. McDougle CJ, Scahill L, McCracken JT, et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. *Child Adolesc Psychiatr Clin North Am* 2000;9:201–224
9. Zarcone JR, Hellings JA, Crandall K, et al. Effects of risperidone on aberrant behavior of persons with developmental disabilities, 1:

- a double-blind crossover study using multiple measures. *Am J Ment Retard* 2001;106:525–538
10. Fava M. Psychopharmacologic treatment of pathologic aggression. *Psychiatr Clin North Am* 1997;20:427–451
 11. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. *J Autism Dev Disord* 1997;27:313–323
 12. Kewley GD. Risperidone in comorbid ADHD and ODD/CD [letter]. *J Am Acad Child Adolesc Psychiatry* 1999;38:1327–1328
 13. Schreier HA. Risperidone for young children with mood disorders and aggressive behaviour. *J Child Adolesc Psychopharmacol* 1998;8:49–59
 14. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*. Washington, DC: American Psychiatric Association; 1994
 15. Daradkeh TK. Parent-teacher reliability in rating children on the 10-items Conners' Rating Scale. *Egypt J Psychiatry* 1993;16:52–56
 16. Guy W. *ECDEU Assessment Manual for Psychopharmacology*. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218–222
 17. Doan RJ. Risperidone for insomnia in PDDs [letter]. *Can J Psychiatry* 1998;43:1050–1051
 18. Khan BU. Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. *J Autism Dev Disord* 1997;27:479–489
 19. Dartnall NA, Holmes JP, Morgan SN, et al. Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. *J Autism Dev Disord* 1999;29:87–91
 20. Helligs JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. *J Child Adolesc Psychopharmacol* 2001;11:229–238
 21. Carroll NB, Boehm KE, Strickland RT. Chorea and tardive dyskinesia in a patient taking risperidone [letter]. *J Clin Psychiatry* 1999;60:485–487
 22. Malone RP, Maislin G, Choudhury MS, et al. Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. *J Am Acad Child Adolesc Psychiatry* 2002;41:140–147
 23. Zuddas A, Di Martino A, Muglia P, et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. *J Child Adolesc Psychopharmacol* 2000;10:79–90
 24. Simon EW, Blubaugh KM, Pippidis M. Substituting traditional antipsychotics with risperidone for individuals with mental retardation. *Ment Retard* 1996;34:359–366
 25. Croonenberghs J, Fegert JM, Findling RL, et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. *J Am Acad Child Adolesc Psychiatry* 2005;44:64–72